TECAR (Transfer of Energy Capacitive and Resistive) therapy is a clinically proven electrotherapy modality that utilizes radiofrequency energy—typically in the range of 300 kHz to 1 MHz—to promote tissue healing, pain management, and functional recovery .The technology works through two complementary modes: CET targets water‑rich tissues such as skin, superficial muscles and the lymphatic system, while RET penetrates deeper to address high‑impedance tissues including deep muscles, tendons, ligaments and bone.
The Rollsystem TECAR device elevates this proven technology by adding a dedicated Roller handle, which combines mechanical massage with deep thermal therapy. This three‑handle configuration allows practitioners to treat multiple tissue layers without the need for separate devices or prolonged patient repositioning—delivering synergistic clinical outcomes in a fraction of the time.
"By integrating RET, CET and the Roller handle into a single platform, we are empowering clinicians with unprecedented versatility," said Carlos Moliner, CEO of RÖS‘S ESTÉTICA, the company behind the Rollsystem brand. "Our goal is to provide a complete solution that addresses the full spectrum of patient needs—from acute injury management and post‑surgical rehabilitation to aesthetic body contouring—all from one machine."
The clinical evidence supporting TECAR therapy continues to grow. A 2025 systematic review and meta‑analysis published in SN Comprehensive Clinical Medicine evaluated TECAR therapy for pain management in sports‑related musculoskeletal pathologies. The analysis, which included eight studies with 399 participants, demonstrated a significant reduction in pain outcomes with a mean difference of −2.26 (95% CI −3.24 to −1.27, p < 0.00001). Medium‑term results showed even greater pain reductions, with a mean difference of −2.64.
A separate clinical commentary published in the International Journal of Sports Physical Therapy (April 2025) further confirmed that TECAR therapy effectively reduces pain, improves range of motion, and facilitates tissue regeneration, with promising results for conditions including tendonitis, ligament sprains and spasticity in stroke survivors-27.
The Rollsystem TECAR system with its integrated roller mechanism expands these benefits by enabling:
Faster rehabilitation times through combined thermal and mechanical stimulation
Reduced edema and inflammation via enhanced lymphatic drainage
Improved tissue mobility and scar remodeling for post‑surgical patients
Enhanced patient comfort through ergonomic rolling action
The 3‑in‑1 design makes the Rollsystem TECAR therapy device suitable for a wide range of professional settings:
Physical Therapy & Sports Rehabilitation – Acute and chronic injury management, tendinopathies, muscle strains, ligament sprains, and delayed‑onset muscle soreness (DOMS)
Aesthetic Medicine – Cellulite reduction, skin tightening, localized fat treatment, and post‑liposuction recovery
Post‑operative & Postpartum Care – Scar management, edema reduction, perineal repair, and cesarean section recovery
Geriatric Care – Osteoarthritis, joint pain, mobility improvement, and fall prevention
Occupational Health – Repetitive strain injuries including carpal tunnel syndrome and plantar fasciitis
The device also supports adjustable frequency settings (300 kHz – 1 MHz), allowing clinicians to fine‑tune penetration depth and thermal effect for individualized patient needs.
The launch comes at a time of robust growth in the TECAR therapy market. Global market research indicates that the TECAR therapy systems market is experiencing strong expansion, driven by increasing demand for non‑invasive treatment options in rehabilitation, sports medicine, and aesthetic applications. Key drivers include aging populations, rising incidence of musculoskeletal disorders, and a growing preference for non‑surgical therapeutic modalities.
Leading industry players are actively innovating in this space. In May 2025, INDIBA launched its COMPACT Series of portable TECAR devices, while in October 2025, RheeGen announced a strategic partnership with Winback to integrate regenerative formulations with TECAR‑based recovery technologies.
The Asia‑Pacific region is projected to experience the highest compound annual growth rate (CAGR) in TECAR therapy adoption, driven by increasing healthcare investments and rising awareness of advanced physiotherapy technologies. North America currently leads the market with a 35% share, followed by Europe at 30%.
The Rollsystem TECAR therapy device is designed with comprehensive safety features. However, as with all therapeutic modalities, certain contraindications apply. The device should not be used on individuals with active tumors or cancer in the treatment area, implanted pacemakers or other electronic devices, during pregnancy, or on areas with active infections, thrombophlebitis, or bleeding disorders. Clinicians are advised to conduct thorough patient assessments prior to treatment.
Rollsystem is a brand of RÖS‘S ESTÉTICA, a Barcelona‑based company dedicated to developing innovative solutions for physiotherapy, rehabilitation, and aesthetic medicine. With a strong commitment to scientific excellence and clinical validation, Rollsystem products are designed to improve patient outcomes through cutting‑edge technology and evidence‑based protocols.
The company recently celebrated its 2024 National Distributors Meeting at its headquarters in Castelldefels, Barcelona, where physiotherapist Anna Abelló presented the scientific foundations of the Rollsystemic platform, reinforcing the brand’s leadership in ultra‑remodeling and systemic diathermy technologies.
The Rollsystem 3‑in‑1 TECAR therapy system is available for order immediately. For more information, including technical specifications, clinical studies, and distributor inquiries, please visit the official website or contact the Rollsystem sales team.
